INTRODUCTION: Only 0.5 to 1% of cirrhotic patients has chylous ascites (CA). CA is a rare form of ascites with milky peritoneal fluid that is rich in triglycerides. One study showed that the incidence is approximately 1/20,000 admissions at a university hospital over a 20 year period. Here, we report a case of atraumatic CA found in a cirrhotic patient. CASE DESCRIPTION/METHODS: A 66 year old man with cirrhosis secondary to alcohol abuse and hepatitis C virus, presented with marked abdominal distention and abdominal pain. On examination, the abdomen was soft, diffusely tender, distended with shifting dullness. Laboratory findings showed anemia, leukocytosis, normal AST, ALT, lipase and INR ratio. Paracentesis was performed and showed milky fluid. Ascites fluid analysis revealed leukocytosis with increased neutrophil count, triglyceride of 284 mg/dl and negative adenosine deaminase level and cytology. The results were consistent with spontaneous bacterial peritonitis and antibiotics was started. However, he deteriorated with intractable vomiting and was found to have high grade small bowel obstruction from CT imaging. He was taken to the OR for laparotomy but continued to deteriorate and expired. DISCUSSION: The most common causes of atraumatic chylous ascites are lymphatic anomalies (32%), malignancy (17%), cirrhosis (11%), Mycobacterium (15%), and a variety of uncommon causes (21%). Our patient had grade 3 ascites by International Ascites Club Grading system, cirrhotic liver with portal hypertension and high grade small bowel obstruction. All of those factors increased the pressure on the intestinal lymphatic system leading to CA. Paracentesis showing triglycerides above 200 mg/dl gives the diagnosis. Management consists of treating the underlying etiology. Pharmacologic treatment with Orlistat and octreotide were reported to be effective in CA. Transjugular intrahepatic portosystemic shunt and peritoneovenous shunting have been used in refractory cases. However, our patient had sepsis from spontaneous bacterial peritonitis with Child Pugh class C, and high grade small bowel obstruction which excluded him from the insertion of shunts. Repeated large-volume paracentesis is a reasonable option for patients who have end-stage disease not amenable to medical or surgical treatment. It is imperative to realize the critical condition in patients with CA as the one year mortality rate is high (69%) and appropriate studies should be done immediately to find and treat the underlying etiology.
219 Background: Inhibition of poly adenosine diphosphate ribose polymerase (PARP) enzymes terminates an alternative DNA repair pathway, resulting in synthetic lethality in homologous recombination deficient tumors. Many PARP inhibitors have shown to improve survival in many solid tumors with noteworthy safety concerns. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of gastrointestinal (GI) and hepatic toxicities. Methods: We conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through June 2018. Phase III RCTs that mention GI toxicities and elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Random effects model was applied. Results: 3188 patients from 7 phase III RCTs with breast, ovarian and gastric cancer were eligible. Studies compared olaparib or niraparib or rucaparib versus placebo, olaparib versus single agent chemotherapy, iniparib + gemcitabine / carboplatin (GC) versus GC, veliparib + C versus C and olaparib + paclitaxel versus paclitaxel. The RR of all-grade side effects were as follows: diarrhea, 1.24 (95% CI: 1.08 – 1.42, P = 0.002); nausea, 1.53 (95% CI: 1.16 – 2.02, P = 0.002); vomiting, 1.46 (95% CI: 1.02 – 2.08, P = 0.03); elevated AST, 1.25 (95% CI: 0.58 – 2.67, P = 0.55); and elevated ALT, 1.61 (95% CI: 0.81 – 3.20, P = 0.16). The RR of high-grade side effects were as follows: diarrhea, 1.08 (95% CI: 0.52 – 2.24, P = 0.82); nausea, 1.81 (95% CI: 0.79 – 4.12, P = 0.15); vomiting, 1.99 (95% CI: 1.06 – 3.73, P = 0.03); elevated AST, 1.86 (95% CI: 0.45 – 7.55, P = 0.38); and elevated ALT, 1.33 (95% CI: 0.42 – 4.18, P = 0.62). Conclusions: Our study showed that the risk of developing all grades of vomiting as well as any-grade nausea and diarrhea was high in PARP inhibitors arm, compared to control group. Timely recognition and prompt intervention with good supportive care are entailed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.